Evidence map›Paper›PMID 36090801›Full record

ArticleTherapeutic advances in medical oncology2022

Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.

Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, Satoshi Kano, Yoshitaka Honma, Hideaki Hirai, Natsuki Saigusa, Kohei Akazawa, Kaori Tani, Hiroya Ojiri and 29 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 1 country.

Daisuke KawakitaDepartment of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Hideaki TakahashiDepartment of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.
Satoshi KanoDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Hideaki HiraiDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Natsuki SaigusaDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Kohei AkazawaDepartment of Medical Informatics, Niigata University Medical and Dental Hospital, Chuo-ku, Niigata, Japan.
Kaori TaniDepartment of Medical Informatics, Niigata University Medical and Dental Hospital, Chuo-ku, Niigata, Japan.
Hiroya OjiriDepartment of Radiology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Hiroyuki OzawaDepartment of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Kenji OkamiDepartment of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara, Japan.
Takahito KondoDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan.
Takafumi TogashiDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Chihiro FushimiDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, Minato-ku, Tokyo, Japan.
Tomotaka ShimuraDepartment of Otolaryngology, Showa University Fujigaoka Hospital, Aoba-ku, Yokohama, Japan.
Akira ShimizuDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Isaku OkamotoDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Takuro OkadaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Yorihisa ImanishiDepartment of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Yoshihiro WatanabeDepartment of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Kuninori OtsukaDepartment of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Akihiro SakaiDepartment of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara, Japan.
Koji EbisumotoDepartment of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara, Japan.
Yuichiro SatoDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Keisuke YamazakiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan.
Yushi UekiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan.
Toyoyuki HanazawaDepartment of Otorhinolaryngology/Head & Neck Surgery, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan.
Yuki SaitoDepartment of Otolaryngology - Head and Neck Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Mizuo AndoDepartment of Otorhinolaryngology/Head & Neck Surgery, Okayama University Graduate School of Medicine, Kita-ku, Okayama, Japan.
Takashi MatsukiDepartment of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Minami-ku, Sagamihara, Japan.
Masato NakaguroDepartment of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
Yukiko SatoDivision of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Makoto UranoDepartment of Diagnostic Pathology, Bantane Hospital, Fujita Health University, School of Medicine, Nakagawa-ku, Nagoya, Japan.
Yoshitaka UtsumiDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
Shinji KohsakaDivision of Cellular Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.
Takashi SaotomeDivision of Medical Oncology, Matsudo City Hospital, Matsudo, Japan.
Yuichiro TadaDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan.ORCID https://orcid.org/0000-0002-0159-8660
Tokyo Medical University · JPKeio University · JPNiigata Cancer Center Hospital · JPTokai University · JPMita Hospital · JPNiigata University · JPNiigata University Medical and Dental Hospital · JPChiba University · JPFujita Health University · JPHokkaido University · JPJikei University School of Medicine · JPKitasato University · JPMatsudo City Hospital · JPNagoya City University · JPNagoya University Hospital · JPNational Cancer Center Hospital East · JPOkayama University · JPShowa University Fujigaoka Hospital · JPThe University of Tokyo · JPTokyo Medical University Hachioji Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma (SDC) have been reported in prospective studies. However, the survival benefit of these therapies to conventional therapy remains controversial, and whether HER2-targeted therapy or ADT should be chosen in HER2- and androgen receptor (AR)-positive SDC patients remains unknown. Methods: Overall, 323 LA/RM SDC patients treated at seven institutions between August 1992 and June 2020 were retrospectively enrolled. The primary aim was to analyze the effect of HER2-targeted therapy and ADT on overall survival from the diagnosis of LA/RM disease to death from any cause (OS1). The secondary indicators included the overall response rate (ORR), clinical benefit rate (CBR), overall survival from therapy initiation for LA/RM disease (OS2), progression-free survival (PFS), time to second progression (PFS2), duration of response (DoR), and duration of clinical benefit (DoCB) of HER2-targeted therapy or ADT as first-line therapy for HER2-positive/AR-positive SDC. Results: Patients treated with HER2-targeted therapy or ADT had longer OS1 than those treated without these therapies (Median OS1: historical control, 21.6 months; HER2-targeted therapy, 50.6 months; ADT, 32.8 months; HER2-targeted therapy followed by ADT, 42.4 months; and ADT followed by HER2-targeted therapy, 45.2 months, Conclusion: Patients treated with HER2-targeted therapy and ADT showed longer survival in LA/RM SDC. HER2-targeted therapy can be recommended prior to ADT for HER2-positive/AR-positive SDC. It is warranted to establish a biomarker that could predict the efficacy of clinical benefit or better response in ADT.

Indexed as

androgen deprivation therapyandrogen receptorHER2HER2-targeted therapysalivary duct carcinoma

Identifiers

PMID36090801
PMCPMC9459484
OpenAlexW4294760899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.